![]() |
市場調查報告書
商品編碼
1519433
2024-2032 年按產品、技術(聚合酶鍊式反應、雜交、DNA 定序、微陣列、等溫核酸擴增技術等)、應用、最終用戶和地區分類的分子診斷市場報告Molecular Diagnostics Market Report by Product, Technology (Polymerase Chain Reactions, Hybridization, DNA Sequencing, Microarray, Isothermal Nucleic Acid Amplification Technology, and Others), Application, End Users, and Region 2024-2032 |
2023年全球IMARC Group診斷市場規模達197億美元。傳染病和遺傳性疾病的盛行率日益增加、聚合酶鏈反應(PCR)技術的進步、人口老化的加劇、早期疾病檢測意識的提高以及政府的支持舉措是塑造市場軌蹟的因素。
主要市場促進因素:分子診斷市場的擴張主要是由於慢性病和傳染病的增加,這反過來又導致對準確診斷方法的需求不斷成長。此外,基因組和個人化醫學的不斷進步也促進了分子診斷市場的成長。
主要市場趨勢:實質趨勢包括對 PCR 的需求,因為它準確、快速,以及由於新方法和診斷技術而導致試劑和試劑盒的增加。此外,向非侵入性早期診斷方法的發展也支持了這項需求。
地區趨勢:北美由於擁有先進的醫療基礎設施、更多的研發投資以及對個人化醫療的高度重視而處於世界領先地位。此外,亞太地區面臨資源利用增加和健康相關知識和支出增加的快速發展。
競爭格局:不斷為市場做出貢獻的主要競爭公司有羅氏診斷、雅培實驗室、凱傑、伯樂實驗室、西門子醫療和賽默飛世爾科技等。這些企業大力投資新技術和合作夥伴關係,以保持分子診斷市場佔有率並佔領新領域。
挑戰與機會:障礙是分子診斷的複雜監管和財務狀況。除了挑戰之外,新興市場不斷成長的醫療保健需求以及不斷進步的技術也為醫療保健提供者帶來了新的機遇,這些進步有望提供更好的診斷並擴大市場。
慢性病和傳染病的盛行率不斷上升
市場呈現出驚人的成長速度,這主要是由於急性和慢性疾病病例的增加。癌症、心臟病和感染等疾病發生率的增加凸顯了分子診斷在快速、正確診斷疾病方面的重要作用。這一屬性可以實現更好的患者治療效果,並構成個別反應的個人化治療計劃,從而增加了市場上的分子診斷需求。隨著世界各地健康狀況日益複雜,對新型分子診斷設備的需求不斷增加,這反過來又推動了市場的持續成長。根據衛生部的報告,2016年,非傳染性疾病(NCD)佔所有死亡病例的61%和致殘病例的55%。
基因組學和個人化醫療的技術進步
該行業正在經歷基因組學和個人化醫療的發展,這對於全球分子診斷市場趨勢至關重要。 DNA 定序、基因表現和下一代 DNA 定序(如 RNA)的基因分析創新至關重要,它們改變了診斷方式,並允許識別特定的疾病標記和遺傳傾向。個人化醫療的使用需要根據個人的基因圖譜客製化治療,這就產生了對複雜診斷技術的需求,這種技術能夠準確地破解複雜的遺傳訊息。先進技術和客製化治療之間不斷加強的合作正在擴大市場佔有率。
根據個人化醫療報道,2015年,美國總統歐巴馬發起精準醫療計劃(PMI)。這項舉措使研究人員能夠安全地存取大量基因組資料,從數千個基因組序列開始,可能擴展到一百萬個基因組序列,以進行深入的科學研究。
人口老化加劇和對針對性診斷的需求
由於老年族群中神經退化性疾病和心血管問題等疾病的增加,對有效診斷方法的需求不斷增加。分子診斷提供了早期檢測健康狀況的寶貴功能,從而為方便和改善結果的治療提供了明確的途徑。這一人群的成長趨勢顯著增加了對非侵入性和精確工具的需求,例如晶片實驗室(LOA)技術,這表明越來越多的細分市場越來越傾向於適應這種新的健康要求。這種人口轉變對分子診斷市場分析做出了重大貢獻。
IMARC Group提供了全球分子診斷市場報告各細分市場主要趨勢的分析,以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據產品、技術、應用和最終用戶對市場進行了分類。
試劑和試劑盒
儀器
軟體和服務
試劑和試劑盒主導市場
該報告根據產品提供了詳細的市場細分和分析。這包括試劑和試劑盒、儀器以及軟體和服務。根據該報告,試劑和試劑盒佔最大部分。
由於分子診斷擴展到各個專業醫療領域,市場正在經歷顯著成長,特別是在試劑和試劑盒領域。研究和新穎發明的新範式產生了新穎的測定和測試方法,需要適當的試劑和試劑盒才能可行。慢性病數量的不斷增加使得對快速、可靠的診斷工具的需求變得更加重要,從而推動了這種成長。大公司與研究機構的參與也對新試劑和試劑盒的開發產生影響,因此在增加分子診斷市場收入方面發揮重要作用。
聚合酶鍊式反應 (PCR)
雜交
DNA定序
微陣列
等溫核酸擴增技術(INAAT)
其他
聚合酶鍊式反應 (PCR) 主導市場
該報告基於該技術對市場進行了詳細的細分和分析。這包括聚合酶鍊式反應 (PCR)、雜交、DNA 定序、微陣列、等溫核酸擴增技術 (INAAT) 等。根據該報告,聚合酶鏈反應(PCR)代表了最大的部分。
PCR 領域主導分子診斷市場前景。 PCR 技術改進的出現,包括 qPCR 和 dPCR 的設計和構建,推動了擴增的生化過程,從而提高了靈敏度、準確性和速度。 PCR 的進步使其成為分子診斷中不可或缺的工具。可用於個人化醫療和標靶治療的基因圖譜的精確分析現在對於這些治療至關重要。此外,照護端診斷的進步和 PCR 平台在醫療保健專業人員和患者中的引入使分子檢測變得更加容易,這擴大了其在醫療保健環境中的整合。
傳染病診斷
腫瘤學
基因檢測
血液篩檢
其他
傳染病診斷主導市場
該報告根據應用程式提供了詳細的市場細分和分析。這包括傳染病診斷、腫瘤學、基因檢測、血液篩檢等。根據該報告,傳染病診斷佔最大部分。
分子診斷市場概述解釋說,市場動態與傳染病的快速傳播一致,包括病毒、細菌和真菌感染。疾病的迅速傳播,特別是那些有可能使世界陷入大流行的疾病,迫切需要早期發現機制和使用可行的遏制策略。分子生物學和免疫分析技術在診斷領域的出現,透過提高病原體檢測和抗藥性分型的準確性和速度,徹底改變了這一領域。這項突破為分子診斷創造了一個充滿希望的市場,並顯示預防性健康和監測計畫的強勁成長趨勢。這些措施在醫療參與和阻止感染傳播方面發揮著重要作用。
醫院
實驗室
其他
該報告根據最終用戶對市場進行了詳細的細分和分析。這包括醫院、實驗室等。
北美洲
美國
加拿大
亞太
中國
日本
印度
韓國
澳洲
印尼
其他
歐洲
德國
法國
英國
義大利
西班牙
俄羅斯
其他
拉丁美洲
巴西
墨西哥
其他
中東和非洲
北美表現出明顯的主導地位,佔據最大的分子診斷市場佔有率
市場研究報告還對所有主要區域市場進行了全面分析,其中包括北美(美國和加拿大);歐洲(德國、法國、英國、義大利、西班牙、俄羅斯等);亞太地區(中國、日本、印度、韓國、澳洲、印尼等);拉丁美洲(巴西、墨西哥等);以及中東和非洲。報告稱,北美是分子診斷最大的區域市場。
根據分子診斷市場預測期,由於持久研發創新的強大文化,北美市場正在成長。隨著癌症、心血管疾病和糖尿病等慢性疾病發生率的增加,需要快速、可靠的檢測方法。醫療保健專業人員和患者對個人化醫療理解程度的提高以及其他因素正在推動市場成長。政府對醫療保健現代化援助的發展和分子診斷技術的建立是業務成長的主要經濟驅動力。此外,DTC基因檢測也是提高消費者互動水平並支持分子診斷市場近期機會的重要組成部分。
The global molecular diagnostics market size reached US$ 19.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 33.7 Billion by 2032, exhibiting a growth rate (CAGR) of 6.1% during 2024-2032. The increasing prevalence of infectious diseases and genetic disorders, technological advancements in polymerase chain reaction (PCR), growing aging population, surging awareness of early disease detection, and supportive government initiatives are factors shaping the market's trajectory.
Major Market Drivers: The market for molecular diagnostics is expanding primarily due to rise in chronic and infectious illnesses which in turn is leading to growing demand for accurate diagnostics methods. In addition, the continual advancements in genomic and personalized medicine are contributing to the molecular diagnostics market growth.
Key Market Trends: Substantial trends include the demand for PCR as it is accurate and fast and the increase in reagents and kits due to the new methodologies and diagnostic technologies. Besides, the movement towards non-invasive, early diagnosis approaches is also supporting the demand.
Geographical Trends: North America is the leader in the world, due to the presence of advanced medical infrastructure, more investments in R&D and a great emphasis on personalized medicine. In addition, Asia-Pacific faces a fast development through increasing resource usage and more health-related knowledge and spendings.
Competitive Landscape: The key competitive companies that are constantly contributing to the market are Roche Diagnostics, Abbott Laboratories, QIAGEN, Bio-Rad Laboratories, Siemens Healthineers, and Thermo Fisher Scientific and others. These enterprises invest heavily in the new technologies and partnerships to maintain the molecular diagnostics market share and occupy new territories.
Challenges and Opportunities: The barriers are regulatory intricacies and finances of the molecular diagnostics. Along with the challenges, new opportunities emerge for healthcare providers from the growing healthcare needs in the emerging markets and from the constant technological advances which promise better diagnostics and expand the market.
Increasing prevalence of chronic and infectious diseases
The market is exhibiting an outstanding growth rate which is mainly due to the increasing cases of acute and chronic illnesses. This increase in disease occurrence, including cancer, heart diseases, and infection focuses on the significant role of the molecular diagnostics in giving fast and proper diagnosis of the disease. This attribute enables the better patient outcomes and also constitutes individual response personalized treatment plans, which increases the molecular diagnostics demand in the market. Along with the expanding complexities of health conditions all over the world, the demand for newfangled molecular diagnostic equipment is rising, which in turn perpetuates the market growth. According to a report by the ministry of health, in 2016, non-communicable diseases (NCDs) accounted for 61% of all mortalities and 55% of disability cases.
Technological advancements in genomics and personalized medicine
The sector is experiencing developments in genomics and personalized medicine that are crucial for the global molecular diagnostics market trends. Genetic profiling innovations for DNA sequencing, gene expression, and next-generation DNA sequencing such as RNA are essential and changing the ways of diagnosis and allowing the identification of specific disease markers and genetic predispositions. The utilization of personalized medicine, which entails to tailoring treatment based on the individual's genetic profile, is creating a need for sophisticated diagnostic technologies, that is able to decipher complex genetic information accurately. The rising cooperation between sophisticated technologies and tailored treatments is expanding the market share.
According to the personalized medicine report, in 2015, U.S. President Barack Obama launched the precision medicine initiative (PMI). This initiative offers researchers secure access to an extensive array of genomic data, starting with thousands and potentially expanding to one million genome sequences, for in-depth scientific research.
Rising aging population and demand for targeted diagnostics
The demand for efficient diagnostic method is rising due to rising illnesses, such as neurodegenerative disorders and cardiovascular problems in geriatric populations. Molecular diagnostics offer a valuable functionality of early detection of health conditions, thus providing a clear path for treatment at convenient and improved outcomes. The growing trend of this demographic is significantly increasing demand for non-invasive and accurate tools such as lab-on-a-chip (LOA) technology which is indicative of an increasing market segment's inclination to adapt to this new health requirement. This population shift is a significant contributing to the molecular diagnostics market analysis.
IMARC Group provides an analysis of the key trends in each segment of the global molecular diagnostics market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, technology, application, and end users.
Reagents and Kits
Instruments
Software and Services
Reagents and kits dominate the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes reagents and kits, instruments, and software and services. According to the report, reagents and kits represented the largest segment.
The market is experiencing a significant increase, particularly in the reagents and kits segment, due to the expansion of molecular diagnostics reach into various medical areas of specialization. Fresh paradigms in research and novel inventions generate novel assays and testing methods that require the appropriate reagents and kits to be feasible. The growing number of chronic diseases make the need for fast and dependable diagnostic tools more crucial, driving the increase. Involvement of the major companies with research institutions also has an impact on the development of new reagents and kits, and hence plays a significant part in increasing the molecular diagnostics market revenue.
Polymerase Chain Reactions (PCR)
Hybridization
DNA Sequencing
Microarray
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
Polymerase chain reactions (PCR) dominate the market
The report has provided a detailed breakup and analysis of the market based on the technology. This includes polymerase chain reactions (PCR), hybridization, DNA sequencing, microarray, isothermal nucleic acid amplification technology (INAAT), and others. According to the report, polymerase chain reactions (PCR) represented the largest segment.
The PCR segment is dominating the molecular diagnostics market outlook. The advent of PCR technology refinements, including the designing and constructing of qPCR and dPCR, propel the amplification's biochemical process, thereby improves the sensitivity, accuracy, and speed. Such advancement of PCR has made it an indispensable instrument in molecular diagnostics. Precise analysis of genetic profiles which can be used in personalized medicine and targeted therapies is now essential to these treatments. Besides, the point-of-care diagnostics advancement and PCR platform introduction into both of the healthcare professionals and patients make molecular testing more available this leads broaden its integration among healthcare environments.
Infectious Diseases Diagnostics
Oncology
Genetic Testing
Blood Screening
Others
Infectious diseases diagnostics dominate the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes infectious diseases diagnostics, oncology, genetic testing, blood screening, and others. According to the report, infectious diseases diagnostics represented the largest segment.
The molecular diagnostics market overview explains that the market dynamics are in line with rapid spread of infectious diseases, encompassing viral, bacterial, and fungal infections. The rapid spread of diseases, especially those which have the potential to plunge the world into pandemics, has caused an urgent need for early detection mechanism and the use of viable containment strategies. The advent of molecular biology and immunoassay technologies in diagnostics revolutionized this landscape by enhancing the accuracy and speed of pathogen detection and typing for their resistances. This breakthrough has led to the creation of a promising market for molecular diagnostics and indicates a strong trend of the growth of preventive health and surveillance projects. These measures play an important role in the medical involvement and stopping the spread of infections.
Hospitals
Laboratories
Others
The report has provided a detailed breakup and analysis of the market based on end users. This includes hospitals, laboratories, and others.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest molecular diagnostics market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for molecular diagnostics.
North America market is growing due to the strong culture of perpetual research and development innovation, as per the molecular diagnostics market forecast period. With the increase in the development of chronic diseases, such as cancer, cardiovascular diseases and diabetes, the rapid and reliable detection methods are required. The increased level of personalized medicine understanding in healthcare professionals and patients alongside other factors is propelling the market growth. Development of government aid in the healthcare modernization and the establishment of molecular diagnostics techniques are the major economies drivers in the business growth. Furthermore, DTC genetic testing is also a significant part which improves the level of consumer interaction and supports the molecular diagnostics market recent opportunities.
Abbott Laboratories
Agilent Technologies Inc.
Becton Dickinson and Company
Biomerieux SA
Danaher Corporation
Diasorin Molecular LLC (DiaSorin)
F. Hoffmann-La Roche AG (Roche Holding AG)
Hologic Inc.
Illumina Inc.
Myriad Genetics Inc.
Qiagen
Quidel Corporation
Thermo Fisher Scientific
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Key molecular diagnostics companies are getting involved in the latest trends in the industry, such as Abbott Laboratories and Agilent Technologies Inc. Leading bio-pharmaceutical firms drive the improvements in diagnostic technology through introduction of newer, more precise, and better tested products. Besides, global giants are continuing to grow their presence across various regions with acquisitions, mergers, and different partnerships in order to increase their market share and facilitating the access to new markets. These strategic moves expand their product lines and improve the quality of their activity, catering to the all-time demand for a customized and point-of-care diagnoses. Molecular diagnostics recent developments include a merger of AI and machine learning technologies that better facilitate data analysis and enhance the accuracy of diagnostics.
In May 2023, Becton Dickinson and Company announced to invest US$ 80 million in the construction of its third plant in Ciudad Juarez.
In January 2023, Agilent Technologies and Akoya Biosciences collaborated to develop multiplex-immunohistochemistry diagnostic products for tissue analysis. The companies also agreed to market end-to-end workflow solutions for multiplex assays in the clinical research market.
In April 2023, Abbott announced the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.